Pemazyre savings card: as little as $0 a prescription with commercial insurance

How to pay the least

Ask for the cash price

Pemazyre

We didn’t find one.

Ask your pharmacy for Pemazyre’s cash price, and one or two other pharmacies too.
Pemazyre’s savings card works only with insurance from a job or one you bought.

Compare every option

Brand namePemazyre

Authorized genericpemigatinib

Regular genericpemigatinib

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Pemazyre?

The original

–

Brand nameThe maker’s card

IncyteCARES Savings Program for PEMAZYRE

Savings card from Incyte

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a prescription

Or call 1-855-452-5234.

In the maker’s words

“Eligible patients can receive PEMAZYRE for as little as $0, subject to certain limits…”

From the maker’s offer on incytecares.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Pemazyre itself, from the same company, sold without the brand name, and usually for less. For now Pemazyre is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Bile duct cancer (cholangiocarcinoma) with an FGFR2 change
Myeloid/lymphoid blood cancers with an FGFR1 change

What the FDA label says

PEMAZYRE is a kinase inhibitor indicated:

for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
For the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.

Source: the FDA label for Pemazyre (Incyte Corporation), June 9, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/pemazyre/